Plain-English translation of NCT06756321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CAR T-cell therapy, a treatment that uses your own immune cells that are reprogrammed in a lab to recognize and fight cancer. If you qualify, you'll receive chemotherapy to prepare your body, followed by a single infusion of these modified cells. Researchers will carefully monitor how safe the treatment is and how well it works for people whose blood cancer has come back or stopped responding to other therapies.
When lymphoma or leukemia stops responding to standard treatments like chemotherapy or stem cell transplants, patients have very few options left. This medication is designed to give people with these hard-to-treat cancers another chance at remission by using their own immune system as a weapon against the cancer.
You likely qualify if…
You likely don't qualify if…
First, you'll go through screening and blood tests to confirm you qualify. Next, doctors will collect immune cells from your blood in an outpatient procedure. You'll then receive chemotherapy ( and ) to prepare your body. Finally, you'll receive a single infusion of the reprogrammed CAR T-cells. After that, you'll have multiple follow-up visits involving blood tests, heart monitoring, physical exams, and imaging to check for safety and how well the treatment is working. The study will track how your immune cells expand and function, and measure markers of inflammation and other effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Affiliated Hospital of Nantong University
Collaborators
Shanghai First Song Biotechnology Co., LTD
Enrollment target
~9 participants
Started
September 2023
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hong Liu, MD
Affiliated Hospital of Nantong University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.